Omalizumab (anti-IgE), a humanized murine monoclonal antibody that inhibits binding of IgE to mast cells, can theoretically reduce the anaphylaxis in patients with systemic mastocytosis, and some recent studies have shown beneficial effects.16 The gene discussed is IGHE; the disease is systemic mastocytosis.